2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever

Equities are down this year because of Donald Trump's trade policies. The 47th U.S. president decided to impose steep tariffs on imported goods from most countries, although he has since significantly rolled back -- or at least paused -- these plans.Amid all the volatility, some companies are proving resilient by performing much better than the market. Some of these look like excellent buy-and-hold options, especially for income-seeking investors. Let's consider two such corporations: Amgen (NASDAQ: AMGN) and Novartis (NYSE: NVS).Although President Trump has spared the pharmaceutical industry from tariffs for now, his administration has indicated that could change soon. That means drugmakers like Amgen might see a meaningful effect on their bottom line. According to some CEOs in the industry, tariffs could even lead to less innovation in the field. Still, developing lifesaving drugs is a business that will never be out of style, regardless of economic conditions.Continue reading

Apr 17, 2025 - 14:07

2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever

Equities are down this year because of Donald Trump's trade policies. The 47th U.S. president decided to impose steep tariffs on imported goods from most countries, although he has since significantly rolled back -- or at least paused -- these plans.

Amid all the volatility, some companies are proving resilient by performing much better than the market. Some of these look like excellent buy-and-hold options, especially for income-seeking investors. Let's consider two such corporations: Amgen (NASDAQ: AMGN) and Novartis (NYSE: NVS).

Although President Trump has spared the pharmaceutical industry from tariffs for now, his administration has indicated that could change soon. That means drugmakers like Amgen might see a meaningful effect on their bottom line. According to some CEOs in the industry, tariffs could even lead to less innovation in the field. Still, developing lifesaving drugs is a business that will never be out of style, regardless of economic conditions.